Properties of Fibrinogen Cleaved by Jararhagin, a Metalloproteinase from the Venom of Bothrops jararaca

Summary

Haemorrhagic metalloproteinases from Bothrops jararaca and other venoms degrade vessel-wall and plasma proteins involved in platelet plug and fibrin clot formation. These enzymes also cause proteolytic digestion of fibrinogen which has been suggested to cause defective platelet function. Fibrinogen degradation by jararhagin, a metalloproteinase from B. jararaca, and the effect of jararhagin fibrinogenolysis on both platelet aggregation and fibrin clot formation were investigated. Jararhagin was found to cleave human fibrinogen in the C-terminal region of the Aα-chain giving rise to a 285-290 kDa fibrinogen molecule lacking the Aα-chain RGD 572-574 platelet-binding site. Platelet binding and aggregation of ADP-activated platelets is unaffected by this modification. This indicates that the lost site is not essential for platelet aggregation, and that the remaining platelet binding sites located in the N-terminal portion of Aα chains (RGD 95-97) and the C-terminal of γ chains (dodecapeptide 400-411) are unaffected by jararhagin-digestion of fibrinogen. Fibrin clot formation with thrombin of this remnant fibrinogen molecule was defective, with poor polymerization of fibrin monomers but normal release of FPA. The abnormal polymerization could be explained by the loss of one of the two complementary polymerization sites required for side-by-side association of fibrin protofibrils. Jararhagin-induced inhibition of platelet function, an important cause of haemorrhage in envenomed patients, is not caused by proteolysis of fibrinogen, as had been thought, and the mechanism remains to be elucidated.

• References

• 1 Rosenfeld G. Symptomatology, pathology and treatment of snake bites in South America. . In: Venomous Animals and Their Venoms Bucherl W, Buckley E. (ed). Academic Press; New York: 1971: 345-384
• 2 Kamiguti AS, Cardoso JLC. Haemostatic changes caused by the venoms of South American snakes. Toxicon 1989; 27: 955-963
• 3 Ohsaka A. Hemorrhagic, necrotizing and edema-forming effects of snake venoms. In: Snake Venoms Lee CY. (ed) Springer; Berlin: 1979: 480-546
• 4 Baramova EN, Shannon JD, Bjamason JB, Fox DJW. Degradation of extracellular matrix proteins by hemorrhagic metalloproteinases. Arch Biochem Biophys 1989; 275: 63-71
• 5 Maruyama M, Sugiki M, Yoshida E, Shimaya K, Mihara H. Broad substrate specifity of snake venom fibrinolytic enzymes: possible role in haemorrhage. Toxicon 1992; 30: 1387-1397
• 6 Markland FS. Inventory of α- and β-fibrinogenases from snake venoms. Thromb Haemost 1991; 65: 438-443
• 7 Teng C-M, Huang T-F. Inventory of exogenous inhibitors of platelet aggregation. Thromb Haemost 1991; 65: 624-626
• 8 Ouyang C, Teng C-M, Huang T-F. Characterization of snake venom components acting on blood coagulation and platelet function. Toxicon 1992; 30: 945-966
• 9 Kini RM, Evans HJ. Inhibition of platelet aggregation by a fibrinogenase from Naja nigricollis venom is independent of fibrinogen degradation. Biochim Biophys Acta 1991; 1095: 117-121
• 10 Doolittle RF. Fibrinogen and fibrin. Ann Rev Biochem 1984; 53: 195-229
• 11 Hawiger J, Kloczewiake M, Bednarek MA, Timmons S. Platelet receptor recognition domains on the alpha chain of human fibrinogen: structure-function analysis. Biochemistry 1989; 28: 2909-2914
• 12 Hawiger J, Timmons S, Kloczewiak M, Strong DD, Doolittle RF. γ and α chains of human fibrinogen possess sites reactive with human platelet receptors. Proc Acad Sci USA 1982; 79: 2068-2071
• 13 Kloczewiak M, Timmons S, Lukas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the γ chain Biochemistry 1984; 23: 1767-1774
• 14 Blomback B, Vestermark A. Isolation of fibrinopeptides by chromatography. Arkiv Kemi 1958; 12: 173-182
• 15 Blomback B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 1978; 275: 501-505
• 16 Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in fibrin formation. Proc Natl Acad Sci USA 1980; 77: 1374-1378
• 17 Kudryk B, Reuterby J, Blomback B. Adsorption of plasmic fragment D to thrombin modified fibrinogen-Sepharose. Thromb Res 1973; 2: 297-304
• 18 Kudryk B, Collen D, Woods KR, Blomback B. Evidence for localization of polymerization sites in fibrinogen. J Biol Chem 1974; 249: 3322-3325
• 19 Takeya H, Nishida S, Nishino N, Makinose Y, Omori-Satoh T, Nikai H, Sugihara H, Iwanaga S. Primary structures of platelet aggregation inhibitors (disintegrins) autoproteolytically released from snake venom hemorrhagic metalloproteinases and new fluorogenic peptide substrates for these enzymes. J Biochem 1993; 113: 473-483
• 20 Paine MJI, Desmond HP, Theakston RDG, Crampton JM. Purification, cloning and molecular characterization of a high molecular weight hemorrhagic metalloproteinase, jararhagin, from Bothrops jararaca venom. J Biol Chem 1992; 267: 22869-22876
• 21 Johnson AJ, Kline DL, Alkjaersig N. Assay methods and standard preparations for plasmin, plasminogen and urokinase in purified systems, 1967-1968. Thromb Diath Haemorrh 1969; 21: 259-252
• 22 Lemmli UK. Cleavage of structural proteins during the asssembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 23 Timmons S, Hawiger J. Isolation of human platelets by albumin gradient and gel filtration. Meth Enzymol 1989; 169: 11-21
• 24 Marder VJ, Shulman NR, Carroll WR. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem 1969; 244: 2111-2119
• 25 Peerschke El, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood 1980; 55: 841-847
• 26 Plow EF, Srouji AH, Meyer D, Marguerie G, Ginsberg MH. Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem 1984; 259: 5388-5391
• 27 Gartner TK, Bennett JS. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem 1985; 260: 1189M
• 28 Lam SC-T, Plow EF, Smith MA, Andrieux A, Rickwaer J-J, Marguerie G, Ginsberg MH. Evidence that arginyl-glycyl-aspartate peptides and fibrinogen y chain peptides share a common binding site on platelets. J Biol Chem 1987; 262: 947-950
• 29 Boffa MC, Boffa GA. Correlations between the enzymatic activities and the factors active on blood coagulation and platelet aggregation from the venom of vipera aspia. Bicocha Biophys Acts 1987; 262: 947-950
• 30 Ouyang C, Teng C-M, Chen Y-C. Properties of fibrinogen degradation products produced by a- and (3-fibrinogenases of Trimeresurus mucrosqua-matus snake venom. k Toxicon 1979; 17: 121-126
• 31 Amrani DL, Newman PJ, Meh D, Mosesson MW. The role of fibrinogen A alpha chains in ADP-induced platelet aggregation. Blood 1988; 72: 919-924
• 32 Peerschke EIB, Galakanis DK. Binding of fibrinogen to ADP-treated platelets. Comparison of plasma fibrinogen fractions and early plasmic degradation derivatives. J Lab Clin Med 1983; 101: 453-460
• 33 Peerschke EIB. Irreversible platelet binding interactions occur independently of fibrinogen alpha chain degradation and are not mediated by intact membrane glycoprotein IMIIa complexes. J Lab Clin Med 1988; 111: 84-92
• 34 Abrams CS, Ruggeri ZM, Taub R, Hoxie JR, Nagaswami C, Weisel JM, Shattil SJ. Anti-idiotypic antibodies against an antibody to the platelet glycoproteins (GP) Ilb/IIIa complex mimic GP Ilb/IIIa recognizing fibrinogen. J Biol Chem 1992; 267: 2775-2785
• 35 Cheresh DA, Berliner SA, Vincente V, Ruggeri ZM. Recognition of distinctive adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell 1989; 58: 945-953
• 36 Farrell DH, Thiagarajan P, Chung DW, Davie EW. Role of fibrinogen a and y chain sites in platelet aggregation. Proc Natl Acad Sci USA 1992; 89: 10729-10732
• 37 Laudano AP, Doolittle RF. Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc Natl Acad Sci USA 1978; 75: 3085-3089
• 38 Pandya BV, Cierniewski CS, Budzynski AZ. Conservation of human fibrinogen conformation after cleavage of the Bp chain NH2 terminus. J Biol Chem 1985; 260: 2994-3000
• 39 Doolittle RF, Laudano AP. Synthetic peptide probes and the location of fibrin polymerization sites. Protides Biol Fluids 1980; 28: 311-316
• 40 Shimizu A, Nagel GM, Doolittle RF. Photoaffinity labelling of the primary fibrin polymerization site: isolation and characterization of a labelled cyanogen bromide fragment corresponding to y-chain residues 337-379. Proc Natl Acad Sci USA 1992; 89: 2888-2892
• 41 Ugarova TP, Budzynski AZ. Interactions between complementary sites in the structural D and E domains of human fibrin. J Biol Chem 1992; 267: 13687-1393
• 42 Hasegawa N, Sasaki S. Location of the binding site “b” for lateral polymerization of fibrin. Thromb Res 1990; 57: 183-195
• 43 Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Fibrinogen Marburg: a homologous case of dysfibrinogenemia, lacking amino acids Aα 461-610 (Lys 461 AAA→ Stop TAA). Blood 1992; 80: 1972-1979
• 44 Kamiguti AS, Desmond HP, Theakston RDG, Hay CRM, Zuzel M. Ineffectiveness of the inhibition of the main haemorrhagic metalloproteinase from Bothrops jararaca venom by its only plasma inhibitor, alpha₂-macroglobulin. Biochim Biophys Acta (accpted on 8/2/94)